[1] Liaw Y F, Chu C M. Hepatitis B virus infection[J].The Lancet,2009,373(9663):582-592.
[2] 吴孟超.肝脏外科学[M].2版.上海:上海科学技术文献出版社,上海科技教育出版社,2000:310.
[3] 左琳琳.中药联合恩替卡韦治疗乙肝后肝硬化患者血清中ALT、AST以及AST/ALT变化[J].辽宁中医药大学学报,2016,(9):193-195.
[4] 黄灵跃,施维群,孟庆宇.复方鳖甲软肝片抗肝纤维化的现状及展望[J].江西中医药大学学报,2015,(4):97-99,107.
[5] 王贵强,王福生,成军,等.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
[6] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,27(11):1141-1159.
[7] Chen Y C, Chu C M, Yeh C T, et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study[J].Hepatology international,2007,1(1):267-273.
[8] Singal A K, Salameh H, Kuo Y F, et al.Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B[J].Alimentary pharmacology & therapeutics,2013,38(2):98-106.
[9] Chu C M, Liaw Y F. Hepatitis B surface antigen seroclearance during chronic HBV infection[J].Antivir Ther,2010,15(2):133-143.
[10] 王宪波,孙乐.肝纤维化的中西医结合诊治[J].临床肝胆病杂志,2015,(1):38-41.
[11] 李延玲,翟玉峰,张怀宏.抗病毒疗法对慢性乙型肝炎患者肝癌发病的影响[J].世界华人消化杂志,2014,(35):5516-5520.
[12] 张冲.抗病毒治疗对失代偿肝硬化患者生存时间及肝癌发生的影响[J].肝脏,2016,21(11):931-933.
[13] 刘瑶,吴同玉.中医治疗乙肝肝硬化的研究近况[J].浙江中医药大学学报,2013,(6):823-825.
[14] Yuen M F, Tanaka Y, Fong D Y T, et al.Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B[J].Journal of hepatology,2009,50(1):80-88.